Regulatory approval
Published by the Health Canada. Approved
RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed |